Lupron Depot patents expiration

LUPRON DEPOT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815801 ABBVIE ENDOCRINE INC Controlled release composition and method of producing the same
Jun, 2022

(1 year, 3 months ago)

US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(7 years from now)

Lupron Depot is owned by Abbvie Endocrine Inc.

Lupron Depot contains Leuprolide Acetate.

Lupron Depot has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Lupron Depot are:

  • US8815801

Lupron Depot was authorised for market use on 22 December, 1995.

Lupron Depot is available in injectable;injection dosage forms.

Lupron Depot can be used as palliative treatment of prostate cancer.

The generics of Lupron Depot are possible to be released after 05 February, 2031.

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 22 December, 1995

Treatment: Palliative treatment of prostate cancer


More Information on Dosage

LUPRON DEPOT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic